Havemeyer Place LP Buys Shares of 18,838 Guardant Health, Inc. $GH

Havemeyer Place LP bought a new stake in shares of Guardant Health, Inc. (NASDAQ:GH) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 18,838 shares of the company’s stock, valued at approximately $1,924,000.

Several other large investors have also recently bought and sold shares of GH. V Square Quantitative Management LLC acquired a new position in Guardant Health during the 4th quarter valued at about $27,000. Chesapeake Asset Management LLC acquired a new position in Guardant Health during the 4th quarter valued at about $28,000. Thurston Springer Miller Herd & Titak Inc. acquired a new position in Guardant Health during the 4th quarter valued at about $31,000. Elyxium Wealth LLC acquired a new position in Guardant Health during the 4th quarter valued at about $35,000. Finally, Parallel Advisors LLC increased its stake in Guardant Health by 164.7% during the 4th quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock valued at $36,000 after buying an additional 219 shares during the period. Institutional investors and hedge funds own 92.60% of the company’s stock.

Guardant Health Price Performance

Shares of GH opened at $125.61 on Friday. Guardant Health, Inc. has a one year low of $40.35 and a one year high of $134.28. The company has a 50-day moving average of $99.39 and a two-hundred day moving average of $101.08. The stock has a market cap of $16.66 billion, a price-to-earnings ratio of -37.05 and a beta of 1.61.

Wall Street Analyst Weigh In

GH has been the topic of several research analyst reports. Piper Sandler set a $127.00 target price on shares of Guardant Health in a research note on Thursday, May 21st. Barclays raised their target price on shares of Guardant Health from $115.00 to $120.00 and gave the company an “overweight” rating in a research note on Friday, May 8th. Citigroup raised their price objective on shares of Guardant Health from $135.00 to $150.00 and gave the company a “buy” rating in a research report on Friday, February 20th. Guggenheim lowered shares of Guardant Health from a “buy” rating to a “buy” rating in a research report on Thursday, May 28th. Finally, Evercore upgraded shares of Guardant Health from an “in-line” rating to an “outperform” rating and set a $160.00 price objective for the company in a research report on Tuesday. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Guardant Health has a consensus rating of “Buy” and a consensus target price of $137.80.

Insider Buying and Selling

In other Guardant Health news, Director Steve E. Krognes sold 9,294 shares of the firm’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $132.51, for a total value of $1,231,547.94. Following the completion of the transaction, the director directly owned 10,222 shares in the company, valued at $1,354,517.22. This trade represents a 47.62% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Amirali Talasaz sold 210,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 20th. The stock was sold at an average price of $109.89, for a total transaction of $23,076,900.00. Following the sale, the chief executive officer owned 1,886,504 shares of the company’s stock, valued at approximately $207,307,924.56. This represents a 10.02% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 350,238 shares of company stock valued at $38,538,372. Company insiders own 5.60% of the company’s stock.

Guardant Health Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.